Table 1.
Participant demographics.
| Characteristics n = 62 | Group mean (SD)‡ | Males | Females |
|---|---|---|---|
| Sex: male | 32 | 30 | |
| Age (years) | 62.0 (12.0) | 68.0 (10.5) | 55.0 (11.9)* |
| Height (m) | 1.7 (0.09) | 1.8 (0.05) | 1.6 (0.05)* |
| Weight (kg) | 87.7 (18.0) | 92.5 (14.8) | 82.5 (19.9) |
| Body mass index | 29.3 (5.4) | 28.5 (4.2) | 30.2 (6.5) |
| Race/ethnicity | |||
| African American | 11 | 2 | 9 |
| Caucasian | 46 | 28 | 18 |
| Hispanic | 4 | 2 | 2 |
| Native American | 1 | 0 | 1 |
| Stroke characteristics | |||
| Time (months) after stroke | 61.0 (50.0) | 62.9 (35.9) | 57.9 (61.2) |
| Right side weakness | 31 | 19 | 12 |
| Bilateral deficits | 1 | 1 | 0 |
| LE Fugl-Meyer score | 23.3 (7.2) | 24.7 (6.3) | 21.8 (7.8) |
| Comorbidities for cardiac risk | |||
| Type 2 diabetes mellitus | 21 | 12 | 9 |
| Current smoker | 0 | 0 | 0 |
| Overweight (BMI 25.0–29.9) [24] | 25 | 27.5 (1.5) | 27.6 (1.6) |
| Obese (BMI 30.0 to > 40) [24] | 27 | 33.0 (1.7) | 34.2 (4.6) |
| Medications: | |||
| high blood pressure | 40 | 20 | 20 |
| beta blockers | 21 | 9 | 12 |
| calcium channel blockers | 15 | 5 | 10 |
| ACE inhibitors | 30 | 16 | 14 |
| hyperlipidemia | 17 | 9 | 8 |
‡Data are “n” participants of 62 unless indicated by group mean (SD).